Advocates are calling on House appropriators to adopt the Senate-approved FY2026 NIH funding level of $48.7 billion and to retain Senate language protecting indirect cost policies and multi‑year grant levels. The push warns that reductions or policy shifts could curtail basic and translational research at academic labs and biotech collaborators. The call to action frames NIH funding as a direct determinant of early‑stage discovery pipelines and downstream partnerships that feed industry innovation. Biotech companies reliant on academic partnerships should monitor appropriations as potential headwinds to research continuity and talent pipelines.